Nonetheless, GPR132 agonist activation of a GPR132-Gs-PKA pathway interfered with mTOR signaling and promoted acute myeloid leukemia (AML) cell differentiation, suggesting a therapeutic approach to AML treatment [66]. This evidence concerns the gene MTOR and acute myeloid leukemia.